IV Antibiotics Reference — 15-drug billing & coding rollup

Category overview — IV antibiotics in the HOPD/OPAT revenue cycle Reviewed May 2026

Why this rollup exists: shared billing infrastructure, distinct per-drug PA gates, and a payer push toward OPAT for any course beyond ~14 days.

IV antibiotics rarely look like specialty buy-and-bill drugs at first glance — many are commodity generics dispensed from pharmacy on standard formulary edits. The revenue-cycle complication is what happens at the edges: outpatient parenteral antimicrobial therapy (OPAT) for prolonged courses (endocarditis, osteomyelitis, prosthetic-joint infection, complicated bacteremia), multidrug-resistant organisms (MDROs) that drive use of higher-cost agents subject to step therapy and prior-auth documentation requirements, and handoffs across settings (inpatient discharge to home-infusion; AIC visits during OPAT; oncology-office IV antibiotics in the immunocompromised) where the wrong HCPCS or wrong place of service can sink the claim.

The MDRO landscape is what makes the second half of this rollup matter to billers. MRSA (methicillin-resistant Staphylococcus aureus) is the workhorse MRSA driver for vancomycin, daptomycin, linezolid, and the long-acting lipoglycopeptides (dalbavancin, oritavancin). VRE (vancomycin-resistant Enterococcus) drives linezolid and daptomycin selection. On the gram-negative side, ESBL-producing Enterobacterales remain mostly carbapenem-treatable; CRE (carbapenem-resistant Enterobacterales) and CR Pseudomonas drive ceftazidime-avibactam (Avycaz, J0714), meropenem-vaborbactam (Vabomere, J2186), ceftolozane-tazobactam (Zerbaxa, J0695), and cefiderocol (Fetroja, J0699) — the high-cost agents most likely to be denied without documented susceptibility and ID-consult support. CRAB (carbapenem-resistant Acinetobacter baumannii) is the specific niche for cefiderocol; polymyxins (colistimethate, J0770) and tigecycline (J3243) are reserved salvage agents.

For revenue cycle, the points of failure cluster in three places. First, multi-week courses without an ID consult and OPAT plan documented at initiation get denied on chart review. Second, the high-cost beta-lactam/BLI combos and lipoglycopeptides routinely require step-therapy documentation — payers want to see prior carbapenem or vancomycin failure, contraindication, or microbiologic resistance before they will authorize the newer agent. Third, the handoff from inpatient (DRG-bundled) to outpatient home-infusion produces two parallel claims — the drug J-code from the home-infusion pharmacy and the S-code per-diem or G-code professional service from the infusion provider — that have to land at the right place under the right benefit. This page maps each of those touchpoints, drug by drug.

Class families — gram-positive vs gram-negative vs MDRO salvage Reviewed May 2026

A quick orientation so the dosing and PA tables that follow make sense. Each family has its own coverage spectrum, billing pattern, and step-therapy logic.

Workhorse generics — in scope for context only

For completeness: ampicillin-sulbactam (Unasyn), piperacillin-tazobactam (Zosyn), ceftriaxone, cefepime, and levofloxacin IV are core formulary workhorses commonly used in OPAT and HOPD courses. They are not separately billable as buy-and-bill specialty drugs in most outpatient billing models — pharmacy dispense and the IV admin codes (96365/96366) carry the claim. Where the drug is provided under a home-infusion benefit, the home-infusion pharmacy bills the drug J-code (e.g., J0696 ceftriaxone, J0692 cefepime, J3490/J3590 unclassified) and the per-diem S-code or Medicare G-code carries the services. They are referenced here only because billers triaging an OPAT claim packet often see them alongside the higher-cost agents on this page.

Per-drug dosing matrix FDA labels verified May 2026

Standard adult IV regimens from FDA labels. Renal-dose adjustments are required for most agents — see individual labels. Pediatric dosing not shown.

Worked example — OPAT vancomycin course (BSA 1.8 m², 80 kg, AUC-guided)

OPAT dosing addendum — continuous-infusion alternatives

Some OPAT programs use prolonged or continuous infusion of beta-lactams (cefepime, ceftazidime, piperacillin- tazobactam) to maximize time above MIC. Per the OPAT IDSA 2018 guideline, continuous infusion may improve pharmacodynamic target attainment for difficult-to-treat gram-negative infections. Billing cumulative mg infused over the encounter is the same rule that applies to argatroban-style continuous-titration drugs — do not bill scheduled-dose units. Cross-link: argatroban (J0883/J0884) page for the cumulative-mg pump-log unit math.

Per-drug NDC reference FDA NDC Directory verified May 2026

Representative NDCs only — billers must verify the dispensed NDC at fill, particularly for vancomycin and daptomycin where multiple manufacturer-specific HCPCS codes exist.

Administration codes CPT verified May 2026

IV antibiotics are therapeutic non-chemotherapy infusions. Use the 96365/96366 family, not 96413.

Dalbavancin / oritavancin — single-dose extended infusion

Dalbavancin (J0875) and oritavancin (J2407) are infused over ~30 minutes (Orbactiv ~3 hours for the reconstituted 1,200 mg dose; Kimyrsa reformulation infuses over ~60 minutes). Bill 96365 for the initial infusion and 96366 for each additional hour. Because both are single-dose visits with no follow-up infusion, there is no repeat 96365 across the course — one infusion encounter, one full claim. This is the operational appeal of the long-acting lipoglycopeptides: one visit replaces a 7–14 day OPAT course.

Home infusion — service code layer

When IV antibiotics are delivered via home infusion, the drug J-code stays on the home-infusion pharmacy claim, but the per-diem service code or per-visit professional code is billed by the home-infusion provider on a separate line of service. Common S-codes: S9494 (per diem, IV antibiotic, every 24 hr), S9497 (every 6 hr), S9500 (every 8 hr), S9501 (every 12 hr), S9502 (every 4 hr), S9503 (continuous), S9504 (every other day). Medicare Home Infusion Therapy benefit uses G-codes G0068/G0069/G0070 per visit category.

Modifiers CMS verified May 2026

JW / JZ — single-dose vial rule per CMS CR 12056

Every claim line for a drug supplied in a single-dose container must carry either JW (discarded portion, on a separate line) or JZ (no discarded portion). The rule applies to all the single-dose-vial IV antibiotics on this page — vancomycin SDV, daptomycin SDV, dalbavancin, oritavancin, cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, ceftolozane-tazobactam, telavancin, eravacycline, tigecycline, polymyxin B SDV, colistimethate SDV. Bill the administered mg on the primary line and the discarded mg on a separate line with JW; both pay at ASP+6%.

Multi-dose-vial exclusions

Some manufacturer presentations are multi-dose vials (MDVs) and are exempt from the JW/JZ rule: certain vancomycin presentations, fluconazole pre-mixed bags, linezolid pre-mixed bags. Verify the dispensed NDC against the FDA label closure-system designation. The exemption applies only to true MDV products, not to SDV vials that happen to have leftover drug.

340B modifiers (JG, TB)

For 340B-acquired IV antibiotics in HOPDs, follow your MAC's current 340B modifier policy. JG applies to most 340B drugs in OPPS settings; TB is the informational modifier for sub-rural and certain exempted hospitals. Office-based 340B reporting varies by MAC.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion — common for the initial OPAT visit assessment, the dalbavancin / oritavancin one-time-visit encounter, and any ID consult performed on the day of infusion.

ICD-10-CM by infection site FY2026 verified May 2026

Use the most specific code supported by encounter documentation. Pair with organism-specific B95–B97 codes where applicable; pair with sequelae codes (e.g., sepsis) where the infection drives the encounter.

Site of care & OPAT place of service Verified May 2026

IV antibiotic infusion sites span the full POS range. Standard outpatient encounters bill under CMS-1500 / 837P; inpatient courses bundle into the DRG and are not separately Part B billable. The OPAT layer is where billing complexity concentrates — SNF, home, and AIC each have their own benefit category and claim pathway.

OPAT — the documentation that makes the claim survive

OPAT is the single biggest revenue-cycle topic on this page. Per IDSA 2018 OPAT clinical practice guideline, an OPAT program should include: ID consultation at initiation, a vascular access plan (PICC vs midline vs port), a lab monitoring plan (drug levels for vancomycin, weekly CBC/CMP, CPK for daptomycin), and a step-down plan (transition to oral therapy when clinically appropriate). Most commercial payers and Medicare Advantage plans require documentation of all four elements at PA submission for courses > 14 days.

Claim form field mapping CMS / 837P verified May 2026

Routine outpatient IV antibiotic visit + OPAT home-infusion handoff. Inpatient is DRG-bundled (no separate Part B billing).

Routine outpatient IV antibiotic visit (HOPD or AIC)

OPAT home-infusion handoff — two parallel claims

Payer policy snapshot — OPAT PA requirements Reviewed May 2026

Major commercial plans converged on a common documentation pattern for OPAT. Newer high-cost agents (Avycaz, Vabomere, Zerbaxa, cefiderocol, dalbavancin, oritavancin) carry additional step-therapy edits.

OPAT PA documentation checklist (common to UHC / Aetna / BCBS / Cigna / Humana)

• ID consult attestation at OPAT initiation (in-person, eConsult, or telehealth acceptable per most plans)
• Vascular access plan documented — PICC, midline, or port; expected dwell time
• Lab monitoring plan — agent-specific (e.g., vancomycin AUC levels, daptomycin weekly CPK, polymyxin/colistin SCr q48–72h, telavancin baseline + on-therapy SCr)
• Indication-specific duration with reassessment milestones (e.g., 4–6 wk for native-valve endocarditis, 6–8 wk for osteomyelitis, 2–6 wk for CRBSI per IDSA)
• Step-down plan to oral therapy when clinically appropriate (linezolid, fluconazole, ciprofloxacin all have 100% PO bioavailability)
• Culture & susceptibility documenting the organism and resistance pattern (required for newer agents)

Step therapy — newer beta-lactam combos & lipoglycopeptides

Plan-specific notes

• UnitedHealthcare: Medical drug PA for the agents above; Optum manages site-of-care steering toward home/AIC for OPAT > 7 days when feasible.
• Aetna: Clinical Policy Bulletin coverage criteria aligned with IDSA OPAT guideline; medical exception pathway for off-label dose escalation (e.g., daptomycin 8–10 mg/kg/day for bacteremia).
• BCBS plans: Vary by Plan; most converge on the IDSA 2018 framework. Federal Employee Program follows similar PA patterns to commercial.
• Cigna: Coverage policies match IDSA guideline for OPAT setting; require home-infusion provider in-network for non-emergent home OPAT.
• Medicare LCDs: Most MACs cover IV antibiotics on indication for FDA-approved use under the Part B drug general-coverage framework; OPAT supplies and home-infusion services covered under Home Infusion Therapy benefit (CY2021+).

Medicare reimbursement — per-drug ASP table CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. The page is bound to the live data layer where Q2 2026 entries exist; values without a current-quarter entry are flagged.

Per-drug ASP table — Q2 2026 unless noted

Patient assistance — mostly foundation-based for the infections category Verified May 2026

Patient assistance for IV antibiotics is structurally different from oncology biologics. There is no large-scale, well-funded foundation pipeline analogous to CancerCare or the PAN Foundation oncology funds for infectious-disease indications. Most manufacturer programs are limited to the newer high-cost branded agents. For generic IV antibiotics (vancomycin, daptomycin, linezolid, tigecycline, fluconazole), the financial assistance pathway is usually hospital charity care or the home-infusion provider's internal indigent program — not a manufacturer copay card.

Manufacturer programs — newer branded agents

• Avycaz (ceftazidime-avibactam, J0714) — AbbVie Access. Commercial copay card; patient assistance program for uninsured/underinsured. Phone: 1-800-292-8979. Web: abbviepatientservices.com.
• Vabomere (meropenem-vaborbactam, J2186) — Melinta Therapeutics. Patient assistance program for eligible patients; benefits investigation support. Web: melinta.com.
• Zerbaxa (ceftolozane-tazobactam, J0695) — Merck Patient Assistance. Web: merckhelps.com; phone 1-800-727-5400.
• Fetroja (cefiderocol, J0699) — Shionogi Cares. Patient assistance program for uninsured/underinsured patients. Web: shionogi.com.
• Xerava (eravacycline, J0122) — Innoviva. Manufacturer patient access program; verify current status (program ownership changed with Tetraphase acquisition).
• Vibativ (telavancin, J3095) — Cumberland Pharmaceuticals. Patient assistance program via manufacturer support line.
• Dalvance (dalbavancin, J0875) — AbbVie / Allergan. Commercial copay card; patient assistance program.
• Orbactiv / Kimyrsa (oritavancin, J2407) — Melinta Therapeutics. Patient access program; same support infrastructure as Vabomere.

Independent foundations — limited infectious-disease coverage

• PAN Foundation — Infectious Disease funds. Limited open funds historically; verify current open funds at panfoundation.org. Open funds change frequently — do not assume availability.
• HealthWell Foundation. Limited rare-disease infection coverage. Verify current funds at healthwellfoundation.org.
• CancerCare Co-Payment Assistance. Generally does not cover infectious disease indications — oncology-only.
• Hospital charity care — usually the primary pathway for uninsured/underinsured OPAT patients; DSH and CAH hospitals carry institutional financial-assistance policies.
• 340B-eligible institutions — for hospitals participating in the 340B Drug Pricing Program, 340B-acquired IV antibiotics carry significant institutional cost reduction; not patient-facing copay assistance.

Top denial reasons & how to fix them

Frequently asked questions

When does OPAT billing apply?

Outpatient Parenteral Antimicrobial Therapy (OPAT) applies when a patient is medically stable enough to leave the inpatient setting but still requires IV antibiotic therapy — typically multi-week courses for endocarditis, osteomyelitis, prosthetic-joint infection, complicated bacteremia, or deep-seated abscess. OPAT can be delivered in HOPD infusion suites, freestanding ambulatory infusion centers, an SNF, or the patient's home via home-infusion. Payers nearly always require documented ID consult, vascular access plan, and lab-monitoring plan before approving an OPAT course. The IDSA 2018 OPAT clinical practice guideline is the reference framework.

Dalbavancin vs oritavancin — what's the billing difference?

Both are long-acting lipoglycopeptides for ABSSSI in adults: dalbavancin (Dalvance, J0875, billed at 5 mg = 1 unit) is given as a single 1,500 mg IV infusion (or 1,000 mg then 500 mg one week later); oritavancin (Orbactiv / Kimyrsa, J2407, billed at 10 mg = 1 unit) is given as a single 1,200 mg IV infusion. Dalbavancin's Q2 2026 ASP+6% is approximately $15.003/5 mg; oritavancin (J2407) is approximately $28.567/10 mg. Both are widely used to avoid OPAT lines for relatively simple ABSSSI cases — but plan side-of-care UM has shifted aggressively against single-dose lipoglycopeptides in 2024–2026 because the per-dose drug cost is high. Document failure of or contraindication to oral therapy in the PA submission.

What is the step therapy for newer beta-lactam / beta-lactamase inhibitor combos (Avycaz, Vabomere, Zerbaxa)?

Most commercial plans require documented failure of, intolerance to, or microbiological resistance to a preferred carbapenem (meropenem, imipenem-cilastatin) or piperacillin-tazobactam before approving Avycaz (ceftazidime-avibactam, J0714), Vabomere (meropenem-vaborbactam, J2186), or Zerbaxa (ceftolozane-tazobactam, J0695). Susceptibility/MIC data from a paired culture is the strongest support. For confirmed KPC or other carbapenemase-producing Enterobacterales (CRE), payers will generally bypass step therapy when the lab confirms the resistance mechanism. ID consult attestation strengthens the PA submission.

Home infusion S-code vs medical J-code — which goes on which claim?

When IV antibiotics are delivered via home infusion under the home-infusion benefit, the drug itself is still billed under its J-code (e.g., J0878 for daptomycin) on the home-infusion provider's claim. The S-codes (S9494–S9504 family) cover the per-diem home-infusion services — equipment, supplies, nursing — and are billed separately by the home-infusion provider. Medicare's Home Infusion Therapy benefit (effective 2021) uses G-codes (G0068–G0070) for the per-visit professional service. Don't conflate the drug claim with the services claim; commercial plans process them under different benefit categories.

How does vancomycin therapeutic drug monitoring (TDM) get billed?

Vancomycin TDM is billed as the lab assay separately from the drug claim. Use CPT 80202 for the vancomycin level (trough or AUC-based). AUC-guided dosing per the 2020 IDSA/ASHP/PIDS/SIDP vancomycin guideline typically requires two timed levels per dosing interval for Bayesian modeling. Document the pharmacist or ID consult overseeing the TDM in the chart — payers increasingly ask for evidence of guideline-concordant TDM, especially in OPAT extended courses.

Why is daptomycin used in catheter-related bloodstream infection (CRBSI)?

Daptomycin (J0878) is preferred over vancomycin for MRSA bacteremia and CRBSI when the vancomycin MIC is ≥ 2 µg/mL, when the patient has clinical or microbiologic failure on vancomycin, or when vancomycin is contraindicated. Higher dosing (8–10 mg/kg/day) is commonly used in bacteremia and endocarditis based on IDSA guidance, off-label from the FDA-approved 6 mg/kg label dose; document the IDSA citation and weight-based calculation on the PA. Daptomycin is inactivated by pulmonary surfactant and is not used for pneumonia.

Cefiderocol (Fetroja) for CRAB — when is it indicated?

Cefiderocol (J0699) is a siderophore cephalosporin with reliable activity against carbapenem-resistant Acinetobacter baumannii (CRAB), CR Pseudomonas aeruginosa, and metallo-beta-lactamase-producing Enterobacterales. FDA-labeled indications are complicated UTI and hospital-acquired/ventilator-associated bacterial pneumonia. Most payers require confirmed multidrug-resistant gram-negative isolate with susceptibility data and an ID-consult attestation before approving. Drug cost is high and OPAT use is uncommon — most cefiderocol courses run inpatient and bundle into the DRG.

Tigecycline boxed warning — how does it affect coverage?

Tigecycline (J3243) carries an FDA boxed warning for increased risk of death versus comparators in pooled clinical trials, particularly in ventilator-associated pneumonia (which is not an approved indication). Most payers cover the FDA-labeled indications (complicated intra-abdominal infection, complicated skin/skin- structure infection, community-acquired bacterial pneumonia in adults) when first-line agents are inappropriate. ID consult and documented mechanism for avoiding alternatives strengthen the PA. The boxed warning is one of the reasons many institutions list eravacycline (Xerava, J0122) or other agents as preferred.

Polymyxin B and colistin (J0770) — nephrotoxicity monitoring expectations?

Both colistimethate sodium (J0770) and polymyxin B carry significant nephrotoxicity and neurotoxicity risk and are reserved for multidrug-resistant gram-negative salvage therapy. Payers expect documented serum creatinine baseline and at minimum every 48–72 hours on therapy, with documented dose adjustment for declining renal function. ID consult is essentially mandatory. Colistimethate is dosed as colistin base activity (CBA), and dosing-unit errors (CBA vs colistimethate sodium milligrams vs international units) are a top documentation-error denial source — see the dosing table on this page.

Outpatient cellulitis — IV antibiotic billing in HOPD or AIC?

For uncomplicated outpatient cellulitis in a stable patient, oral therapy is preferred per IDSA SSTI guidelines. IV antibiotics in HOPD or AIC are appropriate when oral therapy has failed, the patient cannot tolerate oral, the organism is resistant, or the infection meets purulent/severe criteria. Common regimens: vancomycin (J3370/J3373) for MRSA, cefazolin or ceftriaxone for streptococcal/MSSA, oritavancin (J2407) or dalbavancin (J0875) as single-dose options to avoid OPAT line placement. Plan documentation must support medical necessity for IV vs oral; many commercial plans have step-therapy edits requiring oral failure first.

Telavancin (Vibativ) — why does it have a boxed warning?

Telavancin (J3095) carries an FDA boxed warning for nephrotoxicity and fetal risk. Baseline and on-therapy serum creatinine are required, and the drug is reserved for situations where vancomycin and daptomycin are inappropriate. Female patients of childbearing potential require a negative pregnancy test before treatment. The boxed warning has effectively limited telavancin's market share — payers and institutional formularies routinely prefer other gram-positive agents.

Source documents

1. IDSA — 2018 Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy
   Norris AH, Shrestha NK, Allison GM, et al. Clin Infect Dis 2018;68(1):e1–e35. The OPAT framework cited across payer policies.
2. IDSA / ASHP / PIDS / SIDP — 2020 Therapeutic Monitoring of Vancomycin Consensus Guideline
   Rybak MJ, Le J, Lodise TP, et al. AUC-guided dosing for serious MRSA infections.
3. IDSA — Treatment of Antimicrobial-Resistant Gram-Negative Infections (latest guidance)
   Guidance on ESBL, CRE, CR Pseudomonas, CRAB, S. maltophilia — updated periodically.
4. DailyMed — FDA labels for vancomycin, daptomycin, linezolid, Avycaz, Vabomere, Zerbaxa, Fetroja, Xerava, tigecycline, colistimethate, polymyxin B, Vibativ, Dalvance, Orbactiv/Kimyrsa, fluconazole
   Current FDA-approved labels for each agent covered.
5. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026.
6. CMS HCPCS Level II Quarterly Updates
   Source for current J-codes (J3370, J3373–J3376, J0878, J0872–J0877, J2020, J2021, J0714, J2186, J0695, J0699, J0122, J3243, J0770, J3095, J0875, J2407, J1450) and unit definitions.
7. CMS — Home Infusion Therapy benefit (HIT, eff. 2021)
   G-code service payment for Medicare home-infusion therapy; categories 1/2/3 differential per drug type.
8. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
   Single-dose container waste billing rule applied across the SDV antibiotics on this page.
9. IDSA — Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections
   SSTI / ABSSSI clinical pathway; underpins step therapy for oritavancin / dalbavancin PA.
10. UnitedHealthcare — Medical Drug Coverage Policies (antibiotic OPAT, Optum Home Delivery Specialty Pharmacy)
11. Aetna Clinical Policy Bulletins — antibiotic / OPAT coverage policies
12. Cigna — Medical Coverage Policies & Home Infusion Therapy

About this page

We maintain this rollup as a living reference for billers and coders working IV antibiotic claims in HOPD, ambulatory infusion, oncology office, SNF, and home-infusion settings. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Why a rollup? Per-drug standalone pages for every IV antibiotic produce lower per-page SEO value than category-level reference pages with clear per-drug subsections. The rollup format also matches how billers actually work the claim — an OPAT packet covers multiple agents over a multi-week course, not a single-drug episode.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 22, 2026 — Initial publication. 15 IV antibiotics across glycopeptide / lipopeptide / oxazolidinone / beta-lactam-BLI combo / siderophore cephalosporin / tetracycline / polymyxin / triazole antifungal families. ASP data: Q2 2026 where current-quarter CMS entries exist. Wave 8 commodity rollup format.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File where a current-quarter entry exists; codes without current-quarter entries (J3370, J2186, polymyxin B J3490) are flagged. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication lists, dosing, and boxed-warning content are verified against the current FDA label revision and the relevant IDSA clinical practice guideline. We do not paraphrase from billing-software vendor blogs.